Effects of oestrogen on cardiovascular events in postmenopausal women
Department of Internal Medicine/Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, U.S.A.
* Correspondence: Dr D. M. Herrington, MD, MHS, Department of Internal Medicine/Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, U.S.A.
Abstract
A number of randomized clinical trials have investigated the role of hormone replacement therapy (HRT) in primary and secondary prevention of clinical and anatomical manifestations of atherosclerosis. There is mounting evidence that HRT does not slow the progression of clinical or anatomical manifestations of atherosclerosis in women with established disease. Indeed, there appears to be a pattern of increased risk among new users of HRT. In contrast, there are encouraging new data that suggest that HRT may be more effective in women who have not yet developed clinical manifestations of coronary disease.
Key Words: Cardiovascular disease • hormone replacement therapy • oestrogen • primary prevention • secondary prevention
References
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
[Abstract/Free Full Text] - Heckbert SR, Weiss NS, Psaty BM. Hormone replacement therapy for secondary prevention of coronary heart disease. [letter]JAMA. 1999;281:795–796
- Grodstein E, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. A prospective, observational study. Ann Intern Med. 2001;135:1–8
[Abstract/Free Full Text] - Wenger NK, Knatterud GL, Canner PL. Early risks of hormone therapy in patients with coronary heart disease. [letter]JAMA. 2000;284:41–43
[Free Full Text] - Clarke S, Kelleher J, Lloyd-Jones H, et al. Transdermal hormone replacement therapy for secondary prevention of coronary heart disease in postmenopausal women. [abstract]Eur Heart J. 2000;21:212 (abstract suppl)
- Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689–696
[Abstract/Free Full Text] - Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol. 1998;105:890–896[Web of Science][Medline]
- Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97:1037–1041
[Abstract/Free Full Text] - Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation. 1999;100:717–722
[Abstract/Free Full Text] - Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716
[Abstract/Free Full Text] - Herrington DM, Vittinghoff E, Hunninghake D, et al. Effects of statin therapy on cardiovascular events and all-cause mortality in women in the Heart and Estrogen/progestin Replacement Study (HERS). [abstract]Circulation. 2000;102(suppl 11):II–837
- Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522–529
[Abstract/Free Full Text] - Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal estrogen replacement on progression of atherosclerosis. A randomized, controlled trial. Arterioscler Thromb Vase Biol. 2001;21:262–268
- Herrington DM, Waters D, Reboussin DM, et al. No effect of long-term hormone replacement on brachial flow-mediated vasodilation in the Estrogen Replacement and Athero sclerosis (ERA) trial. [abstract]Circulation. 2000;102(suppl 11):II–107
- Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis trial. [abstract]Circulation. 2000;102(suppl II):II–837
- Viscoli CM, Brass LM, Keran WN, et al. Effect of oestrogen replacement on risk of recurrent stroke and death in the Women's Estrogen for Stroke Trial (WEST). [abstract]Stroke. 2001;32:329
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||